MED23 Antibody - BSA Free

Immunoprecipitation: MED23 Antibody [NB200-338]

Immunoprecipitation: MED23 Antibody [NB200-338] - Nuclear extract (5 mg) from HeLa cells. Antibody used at 4 ug/5 mg extract.

Western Blot: MED23 Antibody - BSA Free [NB200-338] -

Identification of compound 10 as potent ELF3-MED23 PPI inhibitor.(A) Synthesized compounds were screened to evaluate their inhibitory activity against ELF3–MED23 PPI. All compounds were used at 10 μM for 12 h (n=3, mean +/- S.D.). (B) Cell viability was also measured in parallel using the same conditions as for the reporter gene assay in (A) (n=3, mean +/- S.D.). (C) Changes in the HER2 levels were evaluated by treating NCI-N87 cells with the compounds that exhibited high SEAP inhibitory activity in (A). (D) Effect of compound 3, 5, and 10 on mRNA level of HER2 in NCI-N87 was assessed (16 hr treatment at 10 μM, n=3, mean +/- S.D., ANOVA, ***p<0.001 vs. CON). (E) PPI inhibitory activities of compounds 3 and 10 were evaluated against endogenous ELF3 and MED23.Compound 25 was used as negative control.Figure 3—source data 1.Raw unedited gels for Figure 3C.Figure 3—source data 2.Uncropped and labelled gels for Figure 3C.Figure 3—source data 3.Raw unedited gels for Figure 3E.Figure 3—source data 4.Uncropped and labelled gels for Figure 3E.Raw unedited gels for Figure 3C.Uncropped and labelled gels for Figure 3C.Raw unedited gels for Figure 3E.Uncropped and labelled gels for Figure 3E. Image collected and cropped by CiteAb from the following open publication (https://elifesciences.org/articles/97051), licensed under a CC-BY license. Not internally tested by Novus Biologicals.